Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę "tumors" wg kryterium: Temat


Wyświetlanie 1-3 z 3
Tytuł:
Navigating the treatment landscape in gastroenteropancreatic neuroendocrine neoplasms
Autorzy:
Rogowski, Wojciech
Wachuła, Ewa
Sulżyc-Bielicka, Violetta
Powiązania:
https://bibliotekanauki.pl/articles/1035765.pdf
Data publikacji:
2019
Wydawca:
Medical Education
Tematy:
gastroenteropancreatic neuroendocrine tumors
neuroendocrine tumors
treatment options
Opis:
Gastroenteropancreatic neuroendocrine neoplasms are a large and very diverse group of neoplasms. They are becoming a burning clinical problem because of increasing frequency and diagnosis in the advanced state. The treatment landscape has been changed over the last years. Treatment choice depends on many factors such as the tumor’s type, location, aggressiveness, and hormone-producing capabilities. The main goals of treatment are long-term symptomatic control, antitumor effect, and improvement of the quality of life. The results of the PROMID and CLARINET trials have augmented fundamental position of somatostatin analogs. Our understanding of the biology, genetics of the neoplasms has improved considerably in the last several decades and the spectrum of available therapeutic options is rapidly expanded. The current evidence-based treatment options include everolimus, sunitinib, peptide receptor radionuclide therapy, and chemotherapy. Treatment practice changed as a result of high-quality phase 3 clinical trials which shaped current guidelines; multiple retrospective studies which raised new questions and attempted to fill some of the data gaps. Here we review the treatment options for gastroenteropancreatic neuroendocrine neoplasms, discussing important diagnosis and biomarker-related factors, safety of therapy with special insight into cardiac safety, as well we looked at promising investigative therapies.
Źródło:
OncoReview; 2019, 9, 1; 31-39
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
New integrative PDT method of cancer treatment by means of laser, magnetic therapy and herbal ferromagnetics
Autorzy:
Arakelyan, Hayk S.
Powiązania:
https://bibliotekanauki.pl/articles/773493.pdf
Data publikacji:
2014
Wydawca:
Medical Education
Tematy:
cancer
integrative photodynamic therapy
tumor’s cell
Opis:
Integrative photodynamic therapy (IPDT) of tumors consists of combined use of different curable factors that extremely increase the effectiveness of IPDT. The leading curable effect of PDT is determined by developing of aggressive photochemical reactions in the tumor. The main destructive factor of these reactions is the generation of free radicals that kill tumor’s cells. For PDT efficacy increasing it is necessary to solve the following problems and assure: easiness of production or synthesis; accumulation high selectivity regarding tumor tissue; low toxicity in light and darkness; singled oxygen generation high quant output; promptly elimination from the organism after the treatment procedure; good absorption in spectral intervals most transparent for tissues (red and infrared intervals); optimal interconversion between quant output and fluorescence quant output. PDT effectiveness may be significantly increased by means of: increasing of photosentisizer selectivity and accumulation in tumor tissue; increasing of tumor tissue photochemical destruction caused by photosensitizer. Realization of integrative PDT using Cyber Laser may increase tumor therapy effectiveness to 94–96% and at the same time will establish a new direction in PDT.
Źródło:
OncoReview; 2014, 4, 4; A171-A174
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Changes in the pathomorphological diagnosis of gastrointestinal neuroendocrine neoplasms in 2017
Autorzy:
Nasierowska-Guttmejer, Anna
Powiązania:
https://bibliotekanauki.pl/articles/1062924.pdf
Data publikacji:
2017
Wydawca:
Medical Education
Tematy:
G3 NET
Ki-67 proliferation index
NEC
neuroendocrine carcinoma
neuroendocrine tumors
Opis:
The following changes were introduced in 2017 WHO and TnM classifications: 1. a new group of well-differentiated neuroendocrine tumors with the proliferation index of more than 20% and mitotic count of 20 per 10 hpf (NET G3), formerly classified under neuroendocrine carcinomas (NEC G3) 2. the division of poorly differentiated neuroendocrine tumors (PD NET) with the Ki-67 index of more than 20% into two groups in terms of the degree of differentiation and prognosis: NET G3 and NEC. 3. the replacement of MANEC with MINEN within the mixed group 4. the verification of histological grading (G) criteria 5. new TNM staging criteria, based on ENETS guidelines.
Źródło:
OncoReview; 2017, 7, 3; 109-115
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
    Wyświetlanie 1-3 z 3

    Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies